...
首页> 外文期刊>Brazilian Journal of Microbiology >Identification and biological activity of potential probiotic bacterium isolated from the stomach mucus of breast-fed lamb
【24h】

Identification and biological activity of potential probiotic bacterium isolated from the stomach mucus of breast-fed lamb

机译:从母乳羔羊胃液中分离出的潜在益生菌的鉴定和生物学活性

获取原文
           

摘要

The lactic acid bacterium E isolated from the stomach mucus of breast-fed lamb was identified by sequencing of 16S rDNA fragment and species-specific PCR as Lactobacillus reuteri. Its potential antimicrobial activity and ability to modulate immune system in vitro and in vivo was determined. The growth inhibition of potential pathogens decreased from Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella enterica ser. Minnesota to Escherichia coli. The lowest inhibition activity was observed in the case of Candida albicans. The ability of L. reuteri E to modulate biological activities of human and mouse mononuclear cells was estimated in vitro and in vivo, respectively. The production of IL-1β by monocytes in vitro was significantly induced by L. reuteri E (relative activity 2.47). The ability to modulate biological activities of mononuclear cells by living L. reuteri E cells in vitro in comparison to disintegrated L. reuteri E cells in vivo differed. For example lysozyme activity in vitro was inhibited while in vivo was stimulated (relative activities 0.30 and 1.83, respectively). The peroxidase activity in vitro was stimulated while in vivo was inhibited (relative activities 1.53 and 0.17, respectively). Obtained results indicate that L. reuteri E is potential candidate to be used in probiotic preparations for animals and/or human.
机译:通过对16S rDNA片段测序和物种特异性PCR鉴定从母乳羔羊胃粘液中分离出的乳酸菌为路氏乳杆菌。确定了其潜在的抗微生物活性和体外和体内调节免疫系统的能力。金黄色葡萄球菌,铜绿假单胞菌,肠炎沙门氏菌对潜在病原体的生长抑制作用减弱。明尼苏达州到大肠杆菌。在白色念珠菌的情况下观察到最低的抑制活性。分别在体外和体内估计罗伊氏乳杆菌调节人和小鼠单核细胞生物学活性的能力。罗伊氏乳杆菌显着诱导单核细胞在体外产生IL-1β(相对活性2.47)。与体内崩解的罗伊氏乳杆菌E细胞相比,活体外的罗伊氏乳杆菌E细胞调节单核细胞生物学活性的能力有所不同。例如,体外溶菌酶活性被抑制,而体内刺激则被抑制(相对活性分别为0.30和1.83)。体外过氧化物酶活性被刺激而体内被抑制(相对活性分别为1.53和0.17)。获得的结果表明,罗伊氏乳杆菌是用于动物和/或人类的益生菌制剂的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号